Library / Search & Research Inquiry
Search the Scientific Record
Query graded findings, peer-reviewed papers, clinical trials, and decision ledgers across the archive — or spawn a new autonomous research branch for any unexplored question.
Public scientific archive — do not enter names, dates of birth, or personal medical identifiers. Organises published research; not medical advice. Privacy & copyright notice.
Grounded synthesis for “Maternal spindle transfer (MST)”
In Mitochondrial and Cytoplasmic Transfer Technologies [1], Heterologous Maternal Spindle Transfer (MST) / Pronuclear Transfer (PNT) for Monogenic Disease carries a "Guideline" verdict (UK Newcastle cohort & longitudinal follow-ups; Australian mitochondrial donation clinical licensing frameworks): Reduction of pathogenic mtDNA mutational load to <1-2% at blastocyst stage; successful live births with minimal initial carryover — Highly effective for severe homoplasmic or high-heteroplasmy mtDNA mutations where PGT is ineffective; strictly regulated with mandatory long-term offspring monitoring. [2] In Mitochondrial and Cytoplasmic Transfer Technologies [1], Heterologous MRT (MST/PNT) for Age-Related Infertility & Embryo Arrest carries a "Trial only" verdict (Prospective cohort study of 66 women aged <=46 years with >=5 failed IVF cycles (323 mature oocytes)): Reported increased blastocyst formation and euploidy with live births in previously refractory cohorts — Contested clinical application; lacks randomized sham-controlled evidence and raises substantial ethical, identity, and third-party genetic inheritance dilemmas alongside risk of mtDNA reversion. [3]
[T1] In a systematic review and meta-analysis of over 31 million women, advanced maternal age of 40 years or older was significantly associated with an increased risk of stillbirth (RR 2.16, 95% CI 1.86-2.51), perinatal mortality, intrauterine growth restriction, neonatal death, NICU admission, pre-eclampsia, preterm delivery, cesarean delivery, and maternal mortality compared to younger women. [4] [5] [T1 (debated)] Bioethical distinctions between maternal spindle transfer and pronuclear transfer focus on the moral status of human embryo destruction, alongside wider concerns regarding transgenerational safety, identity, and germline modification. [6] [7] [T1] Mitochondrial replacement therapy techniques, specifically maternal spindle transfer and pronuclear transfer, are effective in minimizing the transmission of pathogenic mitochondrial DNA mutations to offspring in families with inherited mitochondrial diseases. [6] [8]
Calibrated baseline benchmark in Mitochondrial and Cytoplasmic Transfer Technologies [1]: <1% — Initial maternal mtDNA carryover observed at blastocyst stage following maternal spindle transfer, though post-natal reversion occurs (Costa-Borges et al. 2023 / 2025).
Matched interventions in the Evaluated Decision Ledger
| Intervention / Lever | Verdict | Best evidence & measured effect | Discipline |
|---|---|---|---|
| Heterologous Maternal Spindle Transfer (MST) / Pronuclear Transfer (PNT) for Monogenic DiseaseEnucleation and transfer of nuclear genetic material (meiotic spindle or pronuclei) into enucleated healthy donor ooplasm carrying wild-type mitochondria. | Guideline | Reduction of pathogenic mtDNA mutational load to <1-2% at blastocyst stage; successful live births with minimal initial carryoverUK Newcastle cohort & longitudinal follow-ups; Australian mitochondrial donation clinical licensing frameworks | Mitochondrial and Cytoplasmic Transfer Technologies |
| Heterologous MRT (MST/PNT) for Age-Related Infertility & Embryo ArrestUse of healthy young donor ooplasm to rescue age-related cytoplasmic and metabolic defects in recurrent IVF failure. | Trial only | Reported increased blastocyst formation and euploidy with live births in previously refractory cohortsProspective cohort study of 66 women aged <=46 years with >=5 failed IVF cycles (323 mature oocytes) | Mitochondrial and Cytoplasmic Transfer Technologies |
| Autologous Germline Mitochondrial Transfer (AUGMENT)Isolation of mitochondria from putative ovarian oogonial precursor stem cells (OSCs) and co-injection during ICSI. | Not supported | No statistically significant improvement in ongoing pregnancy rate (OR 0.88, 95% CI 0.29-2.67); trial halted early for futilityDouble-blind RCT (Labarta et al., n=57) and commercial registry data | Mitochondrial and Cytoplasmic Transfer Technologies |
| Autologous Somatic Mitochondrial Transfer (ASCENT / Adipose or Urine Stem Cells)Microinjection of mitochondria isolated from autologous patient adipose or urine-derived mesenchymal stem cells into oocytes at ICSI. | Lab only | Preclinical restoration of ATP levels and calcium dynamics; human clinical efficacy and live birth benefits unprovenPilot randomized trial (n=20) and preclinical human oocyte in vitro assays | Mitochondrial and Cytoplasmic Transfer Technologies |
Graded findings (24)
In a longitudinal study of 7 children born after meiotic spindle transfer (MST) for poor oocyte quality, blastocysts exhibited less than 1% maternal mtDNA carryover (n = 19 blastocysts), but maternal mtDNA reversal was observed in children up to 4 years of age.
Mitochondrial reversal poses a key hurdle to the efficacy and long-term stability of germline mitochondrial replacement therapies.
In a longitudinal follow-up of 7 children born after meiotic spindle transfer, initial blastocyst maternal mtDNA carryover was low (<1% across 19 blastocysts), but subsequent mtDNA 'reversal' was relatively common across tissue samples evaluated up to 4 years of age.
Shows that low initial heteroplasmy after maternal spindle transfer may not prevent donor mtDNA replacement by maternal mtDNA over time, impacting the long-term efficacy of mitochondrial replacement therapy.
Maternal Spindle Transfer (MST) into enucleated donor cytoplasm rescues blastocyst development and produces healthy live births carrying 100% parental nuclear DNA in couples with severe repeated IVF arrest.
Prospective clinical pilot trial (Costa-Borges et al. 2023, n=25) resulting in 6 healthy live births with <1% maternal mtDNA carryover.
- First pilot study of maternal spindle transfer for the treatment of repeated in vitro fertilization failure in couples with idiopathic infertility (Fertility and Sterility, 2023, cohort)
Bioethical distinctions between maternal spindle transfer and pronuclear transfer focus on the moral status of human embryo destruction, alongside wider concerns regarding transgenerational safety, identity, and germline modification.
Pronuclear transfer requires the destruction of fertilized zygotes, creating differentiated ethical evaluation relative to unfertilized spindle transfer.
- 25th ANNIVERSARY OF CLONING BY SOMATIC-CELL NUCLEAR TRANSFER: Cloning, mitochondrial replacement and genome editing: 25 years of ethical debate since Dolly (Reproduction, 2021, expert opinion)
- Mitochondrial/Nuclear Transfer: A Literature Review of the Ethical, Legal and Social Issues (Canadian Journal of Bioethics, 2019, systematic review)
- Are there moral differences between maternal spindle transfer and pronuclear transfer? (Medicine Health Care and Philosophy, 2017, expert opinion)
- Mitochondrial replacement therapy and parenthood (Global Bioethics, 2015, expert opinion)
- The ethical challenges of the clinical introduction of mitochondrial replacement techniques (Medicine Health Care and Philosophy, 2015, expert opinion)
- T3 · Observational, largeDebatedMale & Ovarian Gamete Rejuvenation, Spermatogenesis & Follicular Activation →
Maternal spindle transfer (MST) has shown potential in preliminary studies for addressing mitochondrial dysfunction in oocytes, though larger studies are required.
Techniques are complicated by ethical and legislative challenges and concerns regarding heteroplasmy.
- Mitochondrial replacement techniques to resolve mitochondrial dysfunction and ooplasmic deficiencies: where are we now? (Human Reproduction, 2025, rct)
- Mitochondria as therapeutic targets in assisted reproduction. (Human reproduction (Oxford, England), 2024, systematic review)
- T4 · Observational, small or case-basedContestedMitochondrial and Cytoplasmic Transfer Technologies →
In a prospective cohort study of 66 women aged 46 or younger with diminished ovarian reserve and at least five failed IVF cycles, mitochondrial replacement therapy via pronuclear transfer and maternal spindle transfer across 323 mature oocytes enhanced blastocyst euploidy and resulted in live births while preserving maternal nuclear genetic relatedness.
This represents early clinical evidence exploring pronuclear and spindle transfer specifically for age-related oocyte dysfunction rather than monogenic mitochondrial disease.
Maternal Spindle Transfer (MST) replaces senescent oocyte cytoplasm with enucleated donor cytoplasm while preserving 100% of the mother's nuclear chromosomes, rescuing blastocyst progression and achieving live births in previously arrested IVF cohorts.
Costa-Borges et al., Fertility and Sterility 2023 prospective trial (n=25).
- First pilot study of maternal spindle transfer for the treatment of repeated in vitro fertilization failure in couples with idiopathic infertility (Fertility and Sterility, 2023, cohort)
- T1 · Synthesis of trialsMitochondrial Replacement Therapy →
Mitochondrial replacement therapy techniques, specifically maternal spindle transfer and pronuclear transfer, are effective in minimizing the transmission of pathogenic mitochondrial DNA mutations to offspring in families with inherited mitochondrial diseases.
Multiple systematic reviews and expert consensus identify these techniques as the primary means to prevent maternal transmission of mitochondrial disorders.
- Recent advances in mitochondrial replacement therapy and its future expectations (Clinical and Translational Discovery, 2025, expert opinion)
- Mitochondria as therapeutic targets in assisted reproduction. (Human reproduction (Oxford, England), 2024, systematic review)
- Mitochondrial DNA Replacement Techniques to Prevent Human Mitochondrial Diseases (International Journal of Molecular Sciences, 2021, systematic review)
- Prospects of Germline Nuclear Transfer in Women With Diminished Ovarian Reserve (Frontiers in Endocrinology, 2021, expert opinion)
- Mitochondrial Genetic Drift after Nuclear Transfer in Oocytes (International Journal of Molecular Sciences, 2020, expert opinion)
- Three-parent babies: Mitochondrial replacement therapies (JBRA, 2020, expert opinion)
- Mitochondrial replacement therapy - a new remedy for defects in reproduction (The Indian Journal of Animal Sciences, 2018, systematic review)
- Mitochondrial replacement therapy and assisted reproductive technology: A paradigm shift toward treatment of genetic diseases in gametes or in early embryos. (Reproductive medicine and biology, 2018, expert opinion)
- Are there moral differences between maternal spindle transfer and pronuclear transfer? (Medicine Health Care and Philosophy, 2017, expert opinion)
Heterologous mitochondrial replacement techniques, including maternal spindle transfer and pronuclear transfer, enable replacement of defective cytoplasm to prevent mtDNA transmission and address refractory infertility, though both face substantial ethical and identity-related debates.
Clinical translation of nuclear transfer approaches must navigate heteroplasmy risks, mitochondrial-nuclear genome mismatch, and ethical debates over germline modification.
- Causes of and Solutions to Mitochondrial Disorders: A Literature Review (International Journal of Molecular Sciences, 2025, systematic review)
- Significance of Mitochondrial Dynamics in Reproductive Physiology: Current and Emerging Horizons in Mitochondrial Therapy for Assisted Reproductive Technologies (Reproductive Medicine and Biology, 2025, expert opinion)
- Novel reproductive technologies to prevent mitochondrial disease (Human Reproduction Update, 2017, systematic review)
- Mitochondrial Replacement: Ethics and Identity (Bioethics, 2015, expert opinion)
Mitochondrial replacement therapy and nuclear transfer techniques, such as spindle-chromosomal complex transfer and pronuclear transfer, are emerging experimental strategies in assisted reproductive technology to address maternally inherited mitochondrial disorders and restore reproductive potential.
Mitochondrial replacement techniques decouple the transmission of nuclear DNA from abnormal maternal mitochondria, though their clinical application and efficacy remain under active investigation.
- Significance of Mitochondrial Dynamics in Reproductive Physiology: Current and Emerging Horizons in Mitochondrial Therapy for Assisted Reproductive Technologies (Reproductive Medicine and Biology, 2025, expert opinion)
- Mitochondrial replacement techniques for treating infertility (Journal of Medical Ethics, 2024, expert opinion)
- Prospects of Germline Nuclear Transfer in Women With Diminished Ovarian Reserve (Frontiers in Endocrinology, 2021, expert opinion)
- Advanced Maternal Age in IVF: Still a Challenge? The Present and the Future of Its Treatment. (Frontiers in endocrinology, 2019, in vitro)
- T4 · Observational, small or case-basedDebatedMitochondrial Replacement Therapy & Ooplasmic Transfer →
Maternal Spindle Transfer into enucleated donor oocytes yields healthy live births with 100% parental nuclear DNA and <1% maternal mitochondrial carryover in couples with repeated embryonic arrest.
Costa-Borges et al., Fertility and Sterility 2023.
- First pilot study of maternal spindle transfer for the treatment of repeated in vitro fertilization failure in couples with idiopathic infertility (Fertility and Sterility, 2023, cohort)
Mitochondrial replacement therapy via pronuclear and maternal spindle transfer into donor oocytes yielded successful fertilization, blastocyst euploidy, and live births in a prospective cohort of 66 patients with diminished ovarian reserve and advanced maternal age up to 46 years across 323 mature oocytes.
MRT represents a frontier intervention to bypass maternal age-related cytoplasmic and mitochondrial deterioration, though ethical and technical debates persist.
Heterologous mitochondrial replacement therapies (maternal spindle, pronuclear, germinal vesicle, and polar body transfer) carry risks of donor heteroplasmy and third-party genetic inheritance, while autologous transfer strategies like AUGMENT have yielded contested efficacy following an RCT showing no benefit over standard IVF.
The clinical utility of both autologous and heterologous mitochondrial replacement techniques remains unsettled due to safety, genetic, and efficacy concerns.
- Mitochondrial replacement techniques to resolve mitochondrial dysfunction and ooplasmic deficiencies: where are we now? (Human Reproduction, 2025, rct)
- T6 · Opinion, news or unverifiedMitochondrial and Cytoplasmic Transfer Technologies →
Germline mitochondrial replacement techniques reconstruct functional oocytes or zygotes using methods including pronuclear transfer, maternal spindle transfer, polar body transfer, and germinal vesicle transfer into enucleated donor ooplasm.
These micromanipulation techniques constitute the established technological avenues for heterologous germline mitochondrial replacement therapy.
- Emerging therapeutic strategies for mitochondrial DNA-related diseases (Cell Reports Medicine, 2026, expert opinion)
- Three-parent babies: Mitochondrial replacement therapies (JBRA, 2020, expert opinion)
- T3 · Observational, largeAdvanced Maternal Age & Pregnancy After 40 →
In a cohort of 23,291 singleton pregnancies, maternal age over 40 years was associated with double the risk of hospitalization and neonatal intensive care transfer, with caesarean section rates exceeding 40% in women over 40 and 60% in women over 45.
Establishes quantitative risks of maternal and neonatal morbidity and delivery interventions associated with pregnancy after age 40.
- Impact of maternal age on obstetric and neonatal morbidity: a retrospective cohort study. (BMC pregnancy and childbirth, 2021, cohort)
- Cesarean section on a rise—Does advanced maternal age explain the increase? A population register-based study (PLoS ONE, 2019, cohort)
- The impact of advanced maternal age and parity on obstetric and perinatal outcomes in singleton gestations (Archives of Gynecology and Obstetrics, 2010, cohort)
- T3 · Observational, largeGerm Cell Epigenetic Reprogramming →
Mitochondrial-targeted peptides like SS-31 improve aged oocyte maturation, spindle structure, and embryo development by restoring mitochondrial function, reducing ROS, and altering maternal transcripts.
Demonstrates therapeutic restoration of competency in aged maternal gametes.
- SS-31 improves the quality of maternally aged oocytes by ameliorating mitochondrial function and metabolism. (Journal of ovarian research, 2026, cohort)
- T4 · Observational, small or case-basedAdvanced Maternal Age & Pregnancy After 40 →
Pregnancy at age 50 or older using donor oocyte embryo transfer results in high live birth rates but carries substantial maternal risks, including preeclampsia rates up to 35% and gestational diabetes rates up to 20%.
Extremely advanced maternal age is accompanied by significant cardiovascular and metabolic adaptations despite favorable donor oocyte pregnancy success.
- T5 · Preclinical or mechanisticSenolytic and Anti-Aging Ovarian Therapeutics →
Exogenous melatonin supplementation reduces reactive oxygen species, prevents meiotic spindle and chromosome defects, and suppresses maternal age-related oocyte aneuploidy in mice via a Sirt1/Sod2-dependent pathway.
Melatonin is an antioxidant that directly targets meiotic apparatus degradation in advanced maternal age mouse models.
- Female reproductive capacity preservation: antioxidant strategies in combating ovarian aging and cryopreservation challenges (Frontiers in Endocrinology, 2026, unknown)
- Insufficiency of melatonin in follicular fluid is a reversible cause for advanced maternal age-related aneuploidy in oocytes (Redox Biology, 2019, unknown)
Transfer of euploid embryos via PGT-A improves implantation and reduces miscarriage, yet women aged 38 years and older still experience lower live birth rates compared to younger counterparts.
It remains debated whether non-genetic factors prevent euploid embryo transfer from completely neutralizing age-related declines in reproductive outcomes.
Despite routine clinical application of hyaluronan-enriched transfer media to enhance implantation in assisted reproductive technology, conclusive evidence regarding maternal, obstetric, and perinatal safety remains limited and requires large-scale randomized trial evaluation.
Establishing long-term safety and perinatal complication profiles is required to support the evidence-based use of commercial hyaluronan-enriched culture media.
- Efficacy and safety of hyaluronic acid-enriched transfer medium in women undergoing single blastocyst transfer: a study protocol for a multicentre randomised controlled trial. (BMJ open, 2025, rct)
- Clinical efficacy of hyaluronate-containing embryo transfer medium in IVF/ICSI treatment cycles: a cohort study (Human Reproduction Open, 2021, cohort)
- T5 · Preclinical or mechanisticTranslational & Geroprotective Reproductive Biology →
Clinical management of advanced maternal age in IVF relies on individualized controlled ovarian stimulation, preimplantation genetic testing for aneuploidies, and single embryo transfer, alongside experimental strategies such as nuclear or mitochondrial transfer.
Standard assisted reproductive technologies mitigate age-related aneuploidy and low response, while experimental therapies aim to directly restore oocyte competence.
- Advanced Maternal Age in IVF: Still a Challenge? The Present and the Future of Its Treatment. (Frontiers in endocrinology, 2019, in vitro)
In vitro transfer of autologous urine-derived stem cell mitochondria into aged human oocytes improves mitochondrial content, activity, cytoplasmic calcium levels, embryonic morphology, euploidy rates, and oxidative stress status.
Stem cell-derived autologous mitochondrial transfer provides a potential non-invasive source to rescue metabolic dysfunction in advanced maternal age without donor heteroplasmy concerns, but requires further in vivo validation.
- Autologous non-invasively derived stem cells mitochondria transfer shows therapeutic advantages in human embryo quality rescue. (Biological research, 2023, in vitro)
- T6 · Opinion, news or unverifiedOocyte Quality, Embryo Aneuploidy, and Blastocyst Competence →
Aneuploidy rates in oocytes and embryos are primarily attributed to meiotic spindle assembly defects, which increase with advanced maternal age due to impaired sister chromatid cohesion and kinetochore function.
Understanding the mechanisms of meiotic failure is critical for managing reproductive expectations in women over 40.
- The Meiotic Spindle, Mechanisms of Chromosome Segregation and Aneuploidy in Aging Human Oocytes: An Update Review (Medicina, 2026, unknown)
- Impact of Maternal Age on Oocyte and Embryo Competence. (Frontiers in endocrinology, 2018, expert opinion)
- Ovarian ageing: the role of mitochondria in oocytes and follicles (Human Reproduction Update, 2016, unknown)
- T1 · Synthesis of trialsAdvanced Maternal Age & Pregnancy After 40 →
In a systematic review and meta-analysis of over 31 million women, advanced maternal age of 40 years or older was significantly associated with an increased risk of stillbirth (RR 2.16, 95% CI 1.86-2.51), perinatal mortality, intrauterine growth restriction, neonatal death, NICU admission, pre-eclampsia, preterm delivery, cesarean delivery, and maternal mortality compared to younger women.
Quantifies the escalating perinatal and maternal risks associated with pregnancy past age 40.
- Delayed childbearing and reproductive ageing: a narrative review. (Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2026, expert opinion)
- Maternal and perinatal complications according to maternal age: A systematic review and meta‐analysis (International Journal of Gynecology & Obstetrics, 2022, systematic review)
- Advanced maternal age and adverse pregnancy outcomes: A cohort study (Taiwanese Journal of Obstetrics and Gynecology, 2021, cohort)
- Impact of aging on obstetric outcomes: defining advanced maternal age in Barcelona. (BMC pregnancy and childbirth, 2019, cohort)
- Advanced Maternal Age: Adverse Outcomes of Pregnancy, A Meta-Analysis. (Acta medica portuguesa, 2019, meta analysis)
- Advanced maternal age and adverse pregnancy outcomes: A systematic review and meta-analysis. (PloS one, 2017, meta analysis)
- Maternal age and adverse pregnancy outcome: a cohort study (Ultrasound in Obstetrics and Gynecology, 2013, cohort)
- Advanced Maternal Age and Adverse Pregnancy Outcome: Evidence from a Large Contemporary Cohort (PLoS ONE, 2013, cohort)
Papers, preprints & clinical trials (24)
- First pilot study of maternal spindle transfer for the treatment of repeated in vitro fertilization failure in couples with idiopathic infertility — Nuno Costa-Borges, Keros V, Panagiotis Psathas · Fertility and Sterility · 2023 · cohort · 68 citations
DOI: 10.1016/j.fertnstert.2023.02.008 · Read abstract & full text at official source ↗
- Are there moral differences between maternal spindle transfer and pronuclear transfer? — César Palacios‐González · Medicine Health Care and Philosophy · 2017 · expert opinion · 27 citations
DOI: 10.1007/s11019-017-9772-3 · Read abstract & full text at official source ↗
Indexed in: Mitochondrial Replacement Therapy - Mitochondrial replacement techniques and Mexico's rule of law: on the legality of the first maternal spindle transfer case — César Palacios‐González, María de Jesús Medina Arellano · Journal of Law and the Biosciences · 2017 · case report · 57 citations
DOI: 10.1093/jlb/lsw065 · Read abstract & full text at official source ↗
Indexed in: Mitochondrial Replacement Therapy - Mitochondrial replacement techniques and Mexico's rule of law: on the legality of the first maternal spindle transfer case — Tetsuya Ishii · Journal of Law and the Biosciences · 2017 · 10 citations
DOI: 10.1093/jlb/lsx015 · Read abstract & full text at official source ↗
- O-066 Mitochondrial DNA ‘reversal’ is common in children born following meiotic spindle transfer, potentially reducing the efficacy of mitochondrial replacement therapies — M Savash, Kristina Späth, Dagan Wells · Human Reproduction · 2025 · cohort · 1 citations
DOI: 10.1093/humrep/deaf097.066 · Read abstract & full text at official source ↗
- P-730 Detection of mitochondrial reversal following meiotic spindle transfer: a finding of importance for mitochondrial replacement therapies used for the purpose of avoiding mtDNA disease transmission — Katharina Späth, Nuno Costa-Borges, Eros Nikitos · Human Reproduction · 2023
DOI: 10.1093/humrep/dead093.1049 · Read abstract & full text at official source ↗
Indexed in: Mitochondrial Replacement Therapy - Live birth derived from oocyte spindle transfer to prevent mitochondrial disease. — Zhang J, Liu H, Luo S · Reproductive biomedicine online · 2017 · case report · 202 citations
DOI: 10.1016/j.rbmo.2017.01.013 · Read abstract & full text at official source ↗
- Impact of Euploid Embryo Transfer and Maternal Age on Implantation Outcomes in In Vitro Fertilization-Embryo Transfer (IVF-ET): A Systematic Review. — Belal RE, Majzoub Karamalla SB, Kheiry S · Cureus · 2026 · systematic review · 1 citations
DOI: 10.7759/cureus.109784 · Read abstract & full text at official source ↗
Indexed in: Advanced Maternal Age & Pregnancy After 40 - Modification effect of multiple gestation on the relationship between maternal body mass index and miscarriage in frozen-thawed embryo transfer: a retrospective cohort study. — Luo Z, Wang L, Zhao Z · Reproductive biology and endocrinology : RB&E · 2026 · cohort
DOI: 10.1186/s12958-026-01586-1 · Read abstract & full text at official source ↗
- AI-Assisted Euploid Embryo Selection for Single-Blastocyst Transfer in Women of Advanced Maternal Age — The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · 2026 · rct
Read abstract & full text at official source ↗
Indexed in: Advanced Maternal Age & Pregnancy After 40 - Maternal age and gonadotrophin elevation cooperatively decrease viable ovulated oocytes and increase ootoxicity, chromosome-, and spindle-misalignments: ‘2-Hit’ and ‘FSH-OoToxicity’ mechanisms as new reproductive aging hypotheses — Lori R. Bernstein, Amelia C. L. Mackenzie, Keith Durkin · Molecular Human Reproduction · 2023 · animal · 22 citations
DOI: 10.1093/molehr/gaad030 · Read abstract & full text at official source ↗
- Effect of maternal age on the outcomes of in vitro fertilization and embryo transfer (IVF-ET) — Junhao Yan, Keliang Wu, Rong Tang · Science China Life Sciences · 2012 · cohort · 94 citations
DOI: 10.1007/s11427-012-4357-0 · Read abstract & full text at official source ↗
Indexed in: Patient Stratification & Indications - Prevention of maternal aging-associated oocyte aneuploidy and meiotic spindle defects in mice by dietary and genetic strategies — Kaisa L. Selesniemi, Ho‐Joon Lee, Ailene Muhlhauser · Proceedings of the National Academy of Sciences · 2011 · animal · 201 citations
DOI: 10.1073/pnas.1018793108 · Read abstract & full text at official source ↗
- Maternal and Cord Blood MST1 Levels in Gestational Diabetes Mellitus — Samsun University · 2025 · cohort
- Re-analysis of 166 embryos not transferred after PGS with advanced reproductive maternal age as indication — Charles Hanson, Thorir Hardarson, Kersti Lundin · Human Reproduction · 2009 · cohort · 51 citations
DOI: 10.1093/humrep/dep264 · Read abstract & full text at official source ↗
Indexed in: Patient Stratification & Indications - Enhancing In Vitro Fertilization Outcomes in Advanced Maternal Age — Hsien-Ming Wu, Chyi‐Long Lee · Gynecology and Minimally Invasive Therapy · 2026 · unknown
DOI: 10.4103/gmit.gmit-d-25-00197 · Read abstract & full text at official source ↗
- L26/P-189 Assessment of the meiotic spindle as an objective and non-invasive biomarker of oocyte potential — D González-Abreu, J Aibar Manero, M Marti Vilanova · Human Reproduction · 2026 · cohort
DOI: 10.1093/humrep/deag083.525 · Read abstract & full text at official source ↗
Indexed in: Oocyte Morphology Assessment - O-068 Mitochondrial replacement therapy effectively enhances embryo quality and pregnancy outcomes in patients with advanced maternal age and diminished ovarian reserve — Y Misyura, Birol Aydin, Ulyana Dorofeyeva · Human Reproduction · 2025 · cohort · 2 citations
DOI: 10.1093/humrep/deaf097.068 · Read abstract & full text at official source ↗
- Advanced Maternal Age in IVF: Still a Challenge? The Present and the Future of Its Treatment. — Ubaldi FM, Cimadomo D, Vaiarelli A · Frontiers in endocrinology · 2019 · in vitro · 208 citations
DOI: 10.3389/fendo.2019.00094 · Read abstract & full text at official source ↗
Indexed in: Translational & Geroprotective Reproductive Biology · Inter-Transfer Interval: Immediate vs. Delayed Frozen Embryo Transfer (FET) & Endometrial Reset · Controlled Ovarian Hyperstimulation Inter-Cycle Interval · Dual Ovarian Stimulation and Follicular Wave Dynamics · Perinatal Safety and Maternal Epigenetic Outcomes · Reproductive Nutrition, Dietary Patterns & Ovulatory Function · Clinical Nutrition and Assisted Reproductive Technology Outcomes · Ovarian Reserve & Oocyte Cryopreservation · Mitochondrial Replacement Therapy - Aneuploidy Rates in Advanced Maternal Age Patients Supplemented With Coenzyme Q10 (CoQ10) Versus Those That Are Not: a Pilot Study — Reproductive Endocrinology Associates of Charlotte · 2014 · rct
- A large retrospective study on 1PN embryo transfer supports the need for updated harmonized best practice guidelines. — McPherson NO, Ussher C, Holden S · Human reproduction (Oxford, England) · 2026 · cohort · 1 citations
DOI: 10.1093/humrep/deag098 · Read abstract & full text at official source ↗
Indexed in: Embryo Morphokinetics and Time-Lapse Imaging - Beyond the Scale: Effects of Maternal Obesity on Embryo Morphokinetics and IVF Outcomes — Nir Roguin, Medeia Michaeli, Diana Polotov · Journal of Clinical Medicine · 2026 · cohort
DOI: 10.3390/jcm15062182 · Read abstract & full text at official source ↗
Indexed in: Embryo Morphokinetics and Time-Lapse Imaging - Oocyte vitrification reduces blastocyst yield but preserves reproductive competence in advanced maternal age patients undergoing oocyte accumulation with PGT-A. — Canosa S, Cimadomo D, Maggiulli R · Reproductive biomedicine online · 2026 · cohort
DOI: 10.1016/j.rbmo.2026.105503 · Read abstract & full text at official source ↗
Indexed in: Ovarian Reserve & Oocyte Cryopreservation - Noninvasive Implantation Potential vs Morphology-Based Selection in IVF Single Blastocyst Transfer — Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 2026 · rct
Disciplines & indexed entities
- Maternal Spindle and Pronuclear Transfer0 findings
Analyzes germline nuclear transfer techniques aimed at replacing damaged or aged cytoplasm while preserving parental nuclear genome integrity.
Nuclear and cytoplasmic transfer technologies aimed at reconstructing functional oocytes and overcoming age-associated cytoplasmic decline.
Examines autologous and heterologous mitochondrial transfer, germline mitochondrial replacement therapies, and cytoplasmic transfer aimed at overcoming maternal age-related metabolic and oocyte dysfunction.
Maternal spindle transfer, pronuclear transfer, polar body transfer, heteroplasmy drift, and bioethical-regulatory frameworks.
- Advanced Maternal Age & Pregnancy After 4034 findings
Maternal cardiovascular and metabolic adaptation, hypertensive disorders of pregnancy, gestational diabetes, placental biology, and perinatal outcomes in pregnancy after age 40.
Incidences of postpartum uterine atony, invasive placentation, maternal intensive care admission, and severe maternal morbidity associated with advanced reproductive age.
- Inter-Transfer Interval: Immediate vs. Delayed Frozen Embryo Transfer (FET) & Endometrial Reset14 findings
Immediate next-menstrual-cycle Frozen Embryo Transfer (FET) versus multi-month delayed transfer after a failed embryo transfer or retrieval, cryostorage duration safety at −196°C, HPO-axis washout from programmed HRT to natural ovulatory cycles, CD138 chronic endometritis clearance, and strategic optimization before transferring a final remaining embryo.
Maternal systemic adverse events, ovarian hyperstimulation risks, and neonatal health following dense repeat ovarian stimulation exposures.
Randomised clinical trials, Cochrane meta-analyses, and biophysical mechanisms of hyaluronan-enriched embryo transfer medium (EmbryoGlue, 0.5 mg/mL hyaluronan) versus standard low-hyaluronan transfer media: CD44 and RHAMM receptor-mediated embryo–endometrial apposition, luminal fluid viscosity, live-birth and clinical pregnancy rates across fresh and frozen-thawed embryo transfers (FET), recurrent implantation failure (RIF) and maternal age ≥35 subgroups, multiple pregnancy risk, and ESHRE add-on guidance.
Synthesise the peer-reviewed record on frontier studies on 40+ fertility and new clinical trials: systematic reviews, randomised clinical trials, large cohort studies, quantitative effect sizes, safety signals, and active trials.
- Mitochondrial Function in Gametogenesis20 findings
Study of mitochondrial DNA integrity, ATP production, and oxidative stress management as primary determinants of reproductive cell vitality and quality.
- Reproductive Medicine & Human Fertility12 findings
Physiology, epidemiology, pathology, and clinical interventions in human reproduction across the lifespan, including gametogenesis, ovarian reserve, cryopreservation, endometrial receptivity, andrology, assisted reproductive technology, maternal-fetal medicine, and translational reproductive biology.
- Mitochondrial Replacement Therapy11 findings
Nuclear transfer techniques including maternal spindle transfer and pronuclear transfer to prevent mitochondrial DNA disease transmission.
In vitro gametogenesis, mitochondrial replacement therapy, ovarian tissue cryopreservation and transplantation, mTOR modulation, and intraovarian biologics.
Insulin resistance in pregnancy, diagnostic screening criteria, glycemic control targets, and maternal-neonatal metabolic outcomes.
First- and second-trimester pulsatility index, diastolic notching, pulse wave velocity, and central hemodynamic monitoring.
Gestational cardiac remodeling, arterial stiffness, pre-conception cardiovascular risk stratification, and peripartum cardiomyopathy.
- Maternal Age0 findings
Stratified clinical response to embryo glue across maternal age brackets, specifically evaluating advanced maternal age (AMA) cohorts.
- Maternal Age0 findings
Epidemiological analysis of the independent risk conferred by biological aging on placentation and fetal morphological development.
- Maternal-Fetal Medicine0 findings
Clinical management and risk stratification for pregnancies in older gravidas, focusing on multisystem maternal adaptation and fetal surveillance.
Placenta-on-a-chip and endometrium-on-a-chip microfluidic platforms modeling trophoblast invasion, endocrine communication, and molecular transport under dynamic shear stress.
- Polar Body Transfer Technologies0 findings
Evaluates the utilization of first or second polar body nuclear material transferred into donor enucleated oocytes or zygotes.
- Cryopreservation and Embryo Transfer0 findings
Comparative outcomes of hyaluronan supplementation in fresh embryo transfer cycles versus frozen-thawed embryo transfer (FET) cycles.
Analysis of ICU admission triggers, length of stay, and multi-organ failure rates among parturients aged 40 and older.
- Institute of Life – IASO Hospital (Athens) · Greece (clinic)
Clinical center that conducted the landmark Maternal Spindle Transfer (MST) trial with Embryotools, achieving live births with 100% parental nuclear DNA.
- Embryotools (Parc Científic de Barcelona) · Spain (lab)
Translational embryology research group led by Dr. Nuno Costa-Borges and Dr. Gloria Calderón pioneering Maternal Spindle Transfer micromanipulation.
- Erik Verlinde · Netherlands (person)
Theoretical physicist and string theorist at the University of Amsterdam, known for proposing the entropic/emergent gravity hypothesis.